Janux Therapeutics (JANX) FCF Margin: 2021-2025
Historic FCF Margin for Janux Therapeutics (JANX) over the last 4 years, with Sep 2025 value amounting to -129.49%.
- Janux Therapeutics' FCF Margin rose 38441.00% to -129.49% in Q3 2025 from the same period last year, while for Sep 2025 it was -346.79%, marking a year-over-year decrease of 5694.00%. This contributed to the annual value of -417.20% for FY2024, which is 23138.00% up from last year.
- Per Janux Therapeutics' latest filing, its FCF Margin stood at -129.49% for Q3 2025, which was up 74.80% from -513.90% recorded in Q3 2024.
- Janux Therapeutics' FCF Margin's 5-year high stood at 1,423.68% during Q1 2021, with a 5-year trough of -1,468.68% in Q2 2023.
- Moreover, its 3-year median value for FCF Margin was -498.88% (2023), whereas its average is -629.03%.
- Its FCF Margin has fluctuated over the past 5 years, first slumped by 220,990bps in 2022, then skyrocketed by 135,498bps in 2024.
- Janux Therapeutics' FCF Margin (Quarterly) stood at -687.50% in 2021, then spiked by 19,650bps to -491.00% in 2022, then soared by 6,776bps to -423.24% in 2023, then plummeted by 3,003bps to -513.90% in 2024, then spiked by 38,441bps to -129.49% in 2025.
- Its FCF Margin was -129.49% in Q3 2025, compared to -513.90% in Q3 2024 and -113.70% in Q2 2024.